Optimizing Treatments in Advanced Systemic Mastocytosis With Associated Hematological Neoplasm
April 1, 2025 • ISM Content Hub
Systemic mastocytosis with associated hematologic neoplasm (SM-AHN) presents unique diagnostic and treatment challenges. In this Medscape-certified activity, experts discuss the complex patient journey, from delayed diagnosis to individualized care. Through in-depth case reviews, they explore how KIT mutation burden, symptom profile, and organ involvement guide treatment selection—including targeted therapies like avapritinib, hydroxyurea, or cladribine—and when to consider stem cell transplantation. Advances in KIT inhibitors are transforming outcomes, offering not only symptom relief but potential bridges to curative strategies.
